Literature DB >> 29174740

Retinal changes in patients with major depressive disorder - A controlled optical coherence tomography study.

Carlos Schönfeldt-Lecuona1, Arno Schmidt2, Thomas Kregel2, Jan Kassubek3, Jens Dreyhaupt4, Roland W Freudenmann2, Bernhard J Connemann2, Elmar H Pinkhardt3, Maximilian Gahr2.   

Abstract

BACKGROUND: Recent studies on the pathophysiology of major depression (MD) indicate that degenerative and inflammatory processes may play a role. This finding is supported by magnetic resonance imaging (MRI)-based meta-analysis that show volume reductions in circumscribed areas of the brain in patients with MD. Using optical coherence tomography (OCT), retinal changes have been demonstrated in neurodegenerative disorders. In light of this inflammatory/degenerative hypothesis, we tested whether patients with MD exhibit retinal alterations that might correlate with the severity and duration of the disease.
METHODS: Patients with MD and age- and gender-matched healthy controls were recruited for the measurement of the total volume and thickness of their retina as well as the thicknesses and volumes of five different retinal layers using single-layer-analysis provided by the spectral-domain-OCT.
RESULTS: OCT data from 28 patients with MD and 20 healthy controls were available for evaluation. The exploratory intra-individual group comparison of the two eyes showed a small but significant difference in the retinal total volume (right = 8.69mm3; left = 8.72mm3; p = 0.03) only in patients with MD. There were no other significant differences between the patients with MD and the healthy controls with respect to the OCT measurements. LIMITATIONS: The small group size as well as the absence of correction for multiple testing due to the exploratory design should be considered as limitations of our study.
CONCLUSION: While retinal total volume differs between the eyes of patients with MD, the comparison of retinal parameters between these patients and age- and gender-matched healthy volunteers did not show any differences.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Macula volume; Major depression; OCT; Peripapillary RNFLT; Retinal nerve fiber layer; Retinal pathology

Mesh:

Substances:

Year:  2017        PMID: 29174740     DOI: 10.1016/j.jad.2017.11.077

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  5 in total

1.  Retinal layer abnormalities and their association with clinical and brain measures in psychotic disorders: A preliminary study.

Authors:  Deepthi Bannai; Paulo Lizano; Megan Kasetty; Olivia Lutz; Victor Zeng; Suraj Sarvode; Leo A Kim; Scot Hill; Carol Tamminga; Brett Clementz; Elliot Gershon; Godfrey Pearlson; John B Miller; Matcheri Keshavan
Journal:  Psychiatry Res Neuroimaging       Date:  2020-02-29       Impact factor: 2.376

2.  The Place of Optical Coherence Tomography in Patients with Obsessive Compulsive Disorder.

Authors:  Selim Polat; Berrak Sekeryapan Gediz; Alaattin Cenk Ercan; Muhammet Kaim; Cicek Hocaoglu
Journal:  Eurasian J Med       Date:  2019-10

3.  Application of optical coherence tomography in clinical diagnosis.

Authors:  Yi Wang; Shanshan Liu; Shiliang Lou; Weiqian Zhang; Huaiyu Cai; Xiaodong Chen
Journal:  J Xray Sci Technol       Date:  2019       Impact factor: 1.535

4.  Association of Retinal Nerve Fiber Layer Thickness, an Index of Neurodegeneration, With Depressive Symptoms Over Time.

Authors:  Frank C T van der Heide; Indra L M Steens; Anouk F J Geraets; Yuri D Foreman; Ronald M A Henry; Abraham A Kroon; Carla J H van der Kallen; Thomas T van Sloten; Pieter C Dagnelie; Martien C J M van Dongen; Simone J P M Eussen; Tos T J M Berendschot; Jan S A G Schouten; Carroll A B Webers; Marleen M J van Greevenbroek; Anke Wesselius; Annemarie Koster; Nicolaas C Schaper; Miranda T Schram; Seb Köhler; Coen D A Stehouwer
Journal:  JAMA Netw Open       Date:  2021-11-01

5.  Portable light therapy in the treatment of unipolar non-seasonal major depressive disorder: study protocol for the LUMIDEP randomised controlled trial.

Authors:  Eve Cosker; Marie Moulard; Samuel Schmitt; Karine Angioi-Duprez; Cédric Baumann; Vincent Laprévote; Raymund Schwan; Thomas Schwitzer
Journal:  BMJ Open       Date:  2021-07-09       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.